Human medicines European public assessment report (EPAR): Rixathon, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell;Wegener Granulomatosis;Microscopic Polyangiitis;Pemphigus, Date of authorisation: 15/06/2017

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell;Wegener Granulomatosis;Microscopic Polyangiitis;Pemphigus, Date of authorisation: 15/06/2017, Revision: 12, Status: Authorised